SecBot SecBot
PTAB-TRIAL ·Filed Nov 10, 2026

SPRB

SPRUCE BIOSCIENCES, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed6d 10h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB institution decision (instituted)
Actionable Insight • Neutral

Monitor the PTAB docket for the final written decision, expected within about a year. The outcome could affect Spruce's patent protection for its adrenal rest tumor treatment methods.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$46.67
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.00%
T+1 · $46.20
Vs SPY
−2.32%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $46.67entry
  2. T+1 · 6d ago −1.00%α −2.32% · $46.20
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

Executive Summary

The PTAB instituted a PGR trial on claims of Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. The decision is interlocutory and does not cancel any claims; a final written decision is expected within approximately one year.

PTAB Trial Details

Proceeding
PGR2026-00059
Proceeding Type
PGR (post-grant review)
Decision
Trial instituted
Company Role
Patent owner
Outcome for Patent Owner
Pending (trial to come)
Patent
U.S. 12,569,491
Patent Covers
METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
Challenged Claims
not stated
Next Step
Final written decision expected within approximately one year.

Key Facts

  • PTAB granted institution of PGR2026-00059 on November 10, 2026.
  • Patent U.S. 12,569,491 covers methods for treating testicular and ovarian adrenal rest tumors.
  • Petitioner is Neurocrine Biosciences, Inc.; patent owner is Spruce Biosciences, Inc.
  • Institution is interlocutory; no claims have been cancelled.

Financial Impact

Not stated; the patent's contribution to Spruce's revenue is not quantified in the decision.

Risk Factors

  • A final written decision could cancel some or all challenged claims, potentially weakening Spruce's patent position.
  • The patent's materiality to Spruce's business is not detailed in the decision.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2026-00059-ins-SPRB

US Market Status

Market Closed · Opens in 9h 28m

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 10, 2026